KLRC1 and head and neck squamous cell carcinoma: For HNSCC treatment, monalizumab/IPG2201 (anti-NKG2A) is currently under clinical phase I/II for oral carcinoma treatment (http://clinicaltrials.gov NCT02331875) and for metastatic HNSCC, tested with cetuximab (NCT02331875).